Results 151 to 160 of about 11,506 (271)

Cellular signalling and growth control in vascular development and lymphatic malformations

open access: yes
Dr Kazuhide Shaun Okuda2023-12-15T00:00:00UniversityExcessive lymphatic vessel growth leads to childhood lymphatic malformations, resulting in severe pain and deformities.

core  

Transfer of paracetamol across the placenta and fetal blood–brain barriers and its safety for use in pregnancy

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend Paracetamol (acetaminophen) is commonly taken during pregnancy for pain and fever. To gain a more comprehensive understanding of paracetamol's effects during pregnancy, several elements need to be examined including the transfer of paracetamol across the placenta and into the developing brain, the short‐ and long‐term effects of ...
Yifan Huang, Liam Koehn
wiley   +1 more source

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

open access: yesVIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda   +5 more
wiley   +1 more source

Multidimensional single-cell analysis reveals immune dysfunction and inflammatory response in lymphatic malformations. [PDF]

open access: yesProtein Cell
Chen C   +12 more
europepmc   +1 more source

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review. [PDF]

open access: yesJ Cutan Med Surg
Hollman D   +4 more
europepmc   +1 more source

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle   +5 more
wiley   +1 more source

NRASQ61R Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis

open access: yesPediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Background Kaposiform lymphangiomatosis (KLA) is an aggressive complex lymphatic anomaly. Patients exhibit malformed lymphatic vessels and often develop hemorrhagic effusions and elevated angiopoietin‐2 (Ang‐2) levels. A somatic NRAS p.Q61R (NRASQ61R) mutation has been associated with KLA.
C. Griffin McDaniel   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy